Posts Tagged ‘Fortune 1000’
Top 10 Green IT Initiatives
Thursday, December 1, 2011 18:43 No CommentsManaging the environmental impacts and benefits of IT is vital for companies in today’s world. Not only does it benefit the environment, it also benefits the financial bottom line. Here’s some Top 10 Initiatives happening mostly in the Fortune 1000 and Global 500: 1. LG Electronics USA to Cut Carbon Footprint in Half by 2020 [...]
Sales Intelligence Hunting
Thursday, November 10, 2011 16:47 No CommentsAuthor, Speaker and Strategist Jill Konrath recently did a series of articles whereby she compared sales stories to safari animals. As she rotated through the giraffes and rhinos, I was personally waiting to hear from the King of Beasts, which of course, finally appeared right on queue: King of Beasts And my hunch was right; [...]
Impact of Business Drivers on Sales and Marketing
Tuesday, October 25, 2011 18:03 No CommentsIn today’s highly competitive economy, sales and marketing departments really have to stand out amongst the crowd. The messaging has to be personalized and clearly state what you have to offer that can save them time and money. One of the worst approaches in sales and marketing today is the “data dump” of product features. [...]
Nationwide’s Focus on Data Analytics
Wednesday, October 5, 2011 12:04 No CommentsInsurance remains to be a very competitive industry. Companies, like Nationwide, are focused on the data analytics surrounding the insurance industry. The real competition is based around that data and how to analyze it and use it to their advantage to surpass the competition and create space between them and the rest of the pack. [...]
The Patent Cliff Gets Steeper for Pharma Companies
Friday, July 15, 2011 16:21 No CommentsCompanies in the pharmaceutical industry are beginning to change their Research & Development strategies as they brace themselves for the upcoming “patent cliff” trend. Pharmaceutical sales will significantly decrease as their blockbuster drug patents expire and lose protection against generic competitors. As a result, drug research and their scientists are the ones feeling the burden. [...]
